Uncategorized

Magenta Therapeutics: Developing Novel Treatments In Hematopoietic Stem Cell Transplants — IPO EMPIRE

Magenta Therapeutics (MGTA) was founded in 2015 and launched an IPO on NASDAQ raising $103.8M recently. Shares have increased by >50% since featured in the premium marketplace service. MGTA data by YCharts Pipeline: (Source: prospectus) Antibody-drug conjugate, ADC conditioning programs before hematopoietic stem cell transplant, HSCT: C200: Antibody-drug conjugate, ADC product candidate, targeting CD117, which […]

via Magenta Therapeutics: Developing Novel Treatments In Hematopoietic Stem Cell Transplants — IPO EMPIRE

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s